
CDE Accepts Merck’s Pimicotinib NDA for TGCT Treatment
CDE Accepts Merck’s Pimicotinib NDA for TGCT Treatment Merck, a global leader in science and technology, has officially announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted its application for marketing…












